Samchundang Pharmaceutical Receives Approval for Phase 3 Clinical Trial Plan of Ailia Biosimilar

[Asia Economy Reporter Hyungsoo Park] Samchundang Pharmaceutical announced on the 13th that it has received approval from the U.S. Food and Drug Administration (FDA) for the Phase 3 clinical trial plan of the Eylea biosimilar (SCD411).

The company explained that the clinical trial will compare the efficacy, safety, tolerability, pharmacokinetics, and immunogenicity between SCD411 and Eylea in subjects with neovascular age-related macular degeneration.

This content was produced with the assistance of AI translation services.